(Nevada, Las Vegas) United States, DelveInsight’s, “PD-1 AND PD-L1 Inhibitors- Competitive landscape, 2023,” report provides comprehensive insights about 180+ companies and 200+ drugs in PD-1 and PD-L1 Inhibitors Competitive landscape. It covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the PD-1 and PD-L1 Inhibitors Pipeline Report
-
Over 180 + companies and 200+ pipeline drugs PD-1 and PD-L1 Inhibitors pipeline therapies are in various stages of development, and their anticipated acceptance in the PD-1 and PD-L1 Inhibitors market would significantly increase market revenue.
-
Leading PD-1 and PD-L1 Inhibitors companies developing novel drug candidates to improve the Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis and many others.
-
Promising PD-1 and PD-L1 Inhibitors pipeline therapies in various stages of development includeKX-826, Baricitinib, Etrasimod, Dutasteride, TDM-105795,Baricitinib, ENERGI-F701, Regaine, CKD-498 , CTP-543, PF-06651600 and others.
PD-1 and PD-L1 Inhibitors Overview
PD-1 (programmed cell death protein 1) is found on the surface of cancer cells. It is used by tumors to evade the immune system so blocking its action enables the body to attack and kill cancer. T cells constantly monitor our body for abnormal cells and eliminate them before they can turn into cancer. A key step in tumor development is finding ways to avoid or shut down the immune system. When a T cell becomes activated, it also needs a stop signal in order to make sure it does not get over-activated.
Programmed death-ligand 2 (PD-L2). Programmed death-ligand 1 (PD-L1) in humans is encoded by the CD274 gene. PD-L1 is also known as a cluster of differentiation 274 (CD274). It is a 40 kDa type 1 transmembrane protein that plays a major role in suppressing the immune system during particular events, such as pregnancy, tissue allograft, autoimmune disease, and other disease states such as hepatitis. Normally the immune system reacts to foreign antigens where there is some accumulation in the lymph nodes or spleen which triggers a proliferation of antigen-specific CD8+ T cells. PD-L1 binds to its receptor, PD-1, found on activated T cells, B cells, and myeloid cells to modulate activation or inhibition. PD-1 is a checkpoint protein on immune cells called T cells. It normally acts as a type of “off switch” that helps keep the T cells from attacking other cells in the body. It does this when it attaches to PD-L1, a protein on some normal (and cancer) cells. When PD-1 binds to PD-L1, it basically tells the T cell to leave the other cell alone.
Discover more about the emerging PD-1 and PD-L1 Inhibitors drugs @ PD-1 and PD-L1 Inhibitors Treatment Drugs
PD-1 and PD-L1 Inhibitors Pipeline Therapies and Key Companies
-
Merck: KEYTRUDA
-
AstraZeneca: IMFINZI
-
Tracon Pharmaceuticals Inc.:TECENTRIQ
-
Genentech: Prolgolimab
And many others
Scope of the PD-1 and PD-L1 Inhibitors Pipeline Report
-
Coverage: Global
-
Key PD-1 and PD-L1 Inhibitors Companies: Merck, AstraZeneca, Tracon Pharmaceuticals, Genentech and many others.
-
Key PD-1 and PD-L1 Inhibitors Pipeline Therapies: KEYTRUDA,IMFINZI, TTECENTRIQ, PROLOGOLIMAB, and many others.
Find out more about the PD-1 and PD-L1 Inhibitors treatment options in development @ PD-1 and PD-L1 Inhibitors Clinical Trials
Table of Contents
Introduction
Executive Summary
PD-1 and PD-L1 Inhibitors: Overview
-
Introduction
-
Mechanism of Action
-
Application
-
Limitation
-
Approved Therapies
PDI and PD-L1 Inhibitors -Analytical Perspective: In-depth Commercial Assessment
-
PD1 and PD-L1 Inhibittors Collaboration Analysis by Companies
Competitive Landscape
-
Comparative Assessment of Companies (by therapy, development stage, and technology)
Therapeutic Assessment
-
Assessment by Product Type
-
Assessment by Stage and Product Type
-
Assessment by Route of Administration
-
Assessment by Stage and Route of Administration
-
Assessment by Molecule Type
-
Assessment by Stage and Molecule Type
PD1 and PD-L1 Inhibitors : Company and Product Profiles (Marketed Therapies)
JW Therapeutics
-
Company Overview
Relmacabtagene autoleucel
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Oncolytic Virus Cancer Therapy: Company and Product Profiles (Pipeline Therapies)
Late Stage Products (Registered)
-
Comparative Analysis
CARsgen
-
Company Overview
Zevorcabtagene autoleucel
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
-
Comparative Analysis
Cartesian Therapeutics
-
Company Overview
Descartes 011
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
-
Comparative Analysis
Autolus Therapeutics
-
Company Overview
AUTO-8
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
-
Comparative Analysis
Sana Biotechnology
-
Company Overview
SG299
-
Product Description
-
Research and Development Activities
-
Product Developmental Activities
Drug profiles in the detailed report…..
Inactive Products
-
Comparative Analysis
CAR T – Cell Therapy – Unmet needs
CAR T – Cell Therapy– Market drivers and barriers
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services